Posted on

Update on Awakn’s ketamine study

Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions

Awakn Life Sciences (AWKN) filed an international patent application for its ketamine treatment for behavioural addictions like gambling, gaming, binge eating, and compulsive sexual behaviour. 

Plus, the company shared a bit more info on the “hugely promising” pilot study mentioned last week.

The treatment was found to reduce symptoms of addiction as well as comorbid conditions like depression and anxiety. Some patients no longer qualified for a diagnosis of addiction after the ketamine therapy.

PDF of article

Posted on

Toad venom for Grandma

Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Depression & Anxiety in Alzheimer’s Disease

Could Alzheimer’s patients benefit from one of the most powerful psychedelics? 

Biomind Labs (BMND) will find out in an upcoming study.

The Phase 2 trial, which was just approved by the Argentinian Institutional Review Board, will see if 5-MeO-DMT (a psychedelic found in the venom of the Sonoran Desert toad) can ease depression and anxiety in patients with Alzheimer’s disease.

PDF of article